Global Peptide and Oligonucleotide CDMO Supply, Demand and Key Producers, 2023-2029
The global Peptide and Oligonucleotide CDMO market size is expected to reach $ 3121.4 million by 2029, rising at a market growth of 9.6% CAGR during the forecast period (2023-2029).
This report studies the global Peptide and Oligonucleotide CDMO demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Peptide and Oligonucleotide CDMO, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Peptide and Oligonucleotide CDMO that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Peptide and Oligonucleotide CDMO total market, 2018-2029, (USD Million)
Global Peptide and Oligonucleotide CDMO total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Peptide and Oligonucleotide CDMO total market, key domestic companies and share, (USD Million)
Global Peptide and Oligonucleotide CDMO revenue by player and market share 2018-2023, (USD Million)
Global Peptide and Oligonucleotide CDMO total market by Type, CAGR, 2018-2029, (USD Million)
Global Peptide and Oligonucleotide CDMO total market by Application, CAGR, 2018-2029, (USD Million).
This reports profiles major players in the global Peptide and Oligonucleotide CDMO market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lonza Group Ltd., Thermo Fisher Scientific Inc., Merck KGaA, Catalent, Inc., Genscript Biotech Corporation, Polypeptide Group, Bachem Holding AG, Wuxi Apptec Co., Ltd. and Ajinomoto Co., Inc., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Peptide and Oligonucleotide CDMO market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Peptide and Oligonucleotide CDMO Market, By Region:
1. How big is the global Peptide and Oligonucleotide CDMO market?
2. What is the demand of the global Peptide and Oligonucleotide CDMO market?
3. What is the year over year growth of the global Peptide and Oligonucleotide CDMO market?
4. What is the total value of the global Peptide and Oligonucleotide CDMO market?
5. Who are the major players in the global Peptide and Oligonucleotide CDMO market?
6. What are the growth factors driving the market demand?
This report studies the global Peptide and Oligonucleotide CDMO demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Peptide and Oligonucleotide CDMO, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Peptide and Oligonucleotide CDMO that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Peptide and Oligonucleotide CDMO total market, 2018-2029, (USD Million)
Global Peptide and Oligonucleotide CDMO total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Peptide and Oligonucleotide CDMO total market, key domestic companies and share, (USD Million)
Global Peptide and Oligonucleotide CDMO revenue by player and market share 2018-2023, (USD Million)
Global Peptide and Oligonucleotide CDMO total market by Type, CAGR, 2018-2029, (USD Million)
Global Peptide and Oligonucleotide CDMO total market by Application, CAGR, 2018-2029, (USD Million).
This reports profiles major players in the global Peptide and Oligonucleotide CDMO market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lonza Group Ltd., Thermo Fisher Scientific Inc., Merck KGaA, Catalent, Inc., Genscript Biotech Corporation, Polypeptide Group, Bachem Holding AG, Wuxi Apptec Co., Ltd. and Ajinomoto Co., Inc., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Peptide and Oligonucleotide CDMO market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Peptide and Oligonucleotide CDMO Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Peptide CDMO
- Oligonucleotide CDMO
- Pharmaceutical and Biotechnology Companies
- Research Institutes
- Others
- Lonza Group Ltd.
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Catalent, Inc.
- Genscript Biotech Corporation
- Polypeptide Group
- Bachem Holding AG
- Wuxi Apptec Co., Ltd.
- Ajinomoto Co., Inc.
- Rentschler Biopharma SE
- Corden Pharma GmbH
- Senn Chemicals AG
- Almac Group
- Lonza Custom Manufacturing
- Creative Peptides
- Swiss Customized Synthesis
- Syngene
- Eurogentec
1. How big is the global Peptide and Oligonucleotide CDMO market?
2. What is the demand of the global Peptide and Oligonucleotide CDMO market?
3. What is the year over year growth of the global Peptide and Oligonucleotide CDMO market?
4. What is the total value of the global Peptide and Oligonucleotide CDMO market?
5. Who are the major players in the global Peptide and Oligonucleotide CDMO market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Peptide and Oligonucleotide CDMO Introduction
1.2 World Peptide and Oligonucleotide CDMO Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Peptide and Oligonucleotide CDMO Total Market by Region (by Headquarter Location)
1.3.1 World Peptide and Oligonucleotide CDMO Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Peptide and Oligonucleotide CDMO Market Size (2018-2029)
1.3.3 China Peptide and Oligonucleotide CDMO Market Size (2018-2029)
1.3.4 Europe Peptide and Oligonucleotide CDMO Market Size (2018-2029)
1.3.5 Japan Peptide and Oligonucleotide CDMO Market Size (2018-2029)
1.3.6 South Korea Peptide and Oligonucleotide CDMO Market Size (2018-2029)
1.3.7 ASEAN Peptide and Oligonucleotide CDMO Market Size (2018-2029)
1.3.8 India Peptide and Oligonucleotide CDMO Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Peptide and Oligonucleotide CDMO Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Peptide and Oligonucleotide CDMO Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Peptide and Oligonucleotide CDMO Consumption Value (2018-2029)
2.2 World Peptide and Oligonucleotide CDMO Consumption Value by Region
2.2.1 World Peptide and Oligonucleotide CDMO Consumption Value by Region (2018-2023)
2.2.2 World Peptide and Oligonucleotide CDMO Consumption Value Forecast by Region (2024-2029)
2.3 United States Peptide and Oligonucleotide CDMO Consumption Value (2018-2029)
2.4 China Peptide and Oligonucleotide CDMO Consumption Value (2018-2029)
2.5 Europe Peptide and Oligonucleotide CDMO Consumption Value (2018-2029)
2.6 Japan Peptide and Oligonucleotide CDMO Consumption Value (2018-2029)
2.7 South Korea Peptide and Oligonucleotide CDMO Consumption Value (2018-2029)
2.8 ASEAN Peptide and Oligonucleotide CDMO Consumption Value (2018-2029)
2.9 India Peptide and Oligonucleotide CDMO Consumption Value (2018-2029)
3 WORLD PEPTIDE AND OLIGONUCLEOTIDE CDMO COMPANIES COMPETITIVE ANALYSIS
3.1 World Peptide and Oligonucleotide CDMO Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Peptide and Oligonucleotide CDMO Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Peptide and Oligonucleotide CDMO in 2022
3.2.3 Global Concentration Ratios (CR8) for Peptide and Oligonucleotide CDMO in 2022
3.3 Peptide and Oligonucleotide CDMO Company Evaluation Quadrant
3.4 Peptide and Oligonucleotide CDMO Market: Overall Company Footprint Analysis
3.4.1 Peptide and Oligonucleotide CDMO Market: Region Footprint
3.4.2 Peptide and Oligonucleotide CDMO Market: Company Product Type Footprint
3.4.3 Peptide and Oligonucleotide CDMO Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Peptide and Oligonucleotide CDMO Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Peptide and Oligonucleotide CDMO Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Peptide and Oligonucleotide CDMO Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Peptide and Oligonucleotide CDMO Consumption Value Comparison
4.2.1 United States VS China: Peptide and Oligonucleotide CDMO Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Peptide and Oligonucleotide CDMO Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Peptide and Oligonucleotide CDMO Companies and Market Share, 2018-2023
4.3.1 United States Based Peptide and Oligonucleotide CDMO Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Peptide and Oligonucleotide CDMO Revenue, (2018-2023)
4.4 China Based Companies Peptide and Oligonucleotide CDMO Revenue and Market Share, 2018-2023
4.4.1 China Based Peptide and Oligonucleotide CDMO Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Peptide and Oligonucleotide CDMO Revenue, (2018-2023)
4.5 Rest of World Based Peptide and Oligonucleotide CDMO Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Peptide and Oligonucleotide CDMO Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Peptide and Oligonucleotide CDMO Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Peptide and Oligonucleotide CDMO Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Peptide CDMO
5.2.2 Oligonucleotide CDMO
5.3 Market Segment by Type
5.3.1 World Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
5.3.2 World Peptide and Oligonucleotide CDMO Market Size by Type (2024-2029)
5.3.3 World Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Peptide and Oligonucleotide CDMO Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Pharmaceutical and Biotechnology Companies
6.2.2 Research Institutes
6.2.3 Others
6.3 Market Segment by Application
6.3.1 World Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
6.3.2 World Peptide and Oligonucleotide CDMO Market Size by Application (2024-2029)
6.3.3 World Peptide and Oligonucleotide CDMO Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Lonza Group Ltd.
7.1.1 Lonza Group Ltd. Details
7.1.2 Lonza Group Ltd. Major Business
7.1.3 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Product and Services
7.1.4 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Lonza Group Ltd. Recent Developments/Updates
7.1.6 Lonza Group Ltd. Competitive Strengths & Weaknesses
7.2 Thermo Fisher Scientific Inc.
7.2.1 Thermo Fisher Scientific Inc. Details
7.2.2 Thermo Fisher Scientific Inc. Major Business
7.2.3 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Product and Services
7.2.4 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Thermo Fisher Scientific Inc. Recent Developments/Updates
7.2.6 Thermo Fisher Scientific Inc. Competitive Strengths & Weaknesses
7.3 Merck KGaA
7.3.1 Merck KGaA Details
7.3.2 Merck KGaA Major Business
7.3.3 Merck KGaA Peptide and Oligonucleotide CDMO Product and Services
7.3.4 Merck KGaA Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Merck KGaA Recent Developments/Updates
7.3.6 Merck KGaA Competitive Strengths & Weaknesses
7.4 Catalent, Inc.
7.4.1 Catalent, Inc. Details
7.4.2 Catalent, Inc. Major Business
7.4.3 Catalent, Inc. Peptide and Oligonucleotide CDMO Product and Services
7.4.4 Catalent, Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Catalent, Inc. Recent Developments/Updates
7.4.6 Catalent, Inc. Competitive Strengths & Weaknesses
7.5 Genscript Biotech Corporation
7.5.1 Genscript Biotech Corporation Details
7.5.2 Genscript Biotech Corporation Major Business
7.5.3 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Product and Services
7.5.4 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Genscript Biotech Corporation Recent Developments/Updates
7.5.6 Genscript Biotech Corporation Competitive Strengths & Weaknesses
7.6 Polypeptide Group
7.6.1 Polypeptide Group Details
7.6.2 Polypeptide Group Major Business
7.6.3 Polypeptide Group Peptide and Oligonucleotide CDMO Product and Services
7.6.4 Polypeptide Group Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Polypeptide Group Recent Developments/Updates
7.6.6 Polypeptide Group Competitive Strengths & Weaknesses
7.7 Bachem Holding AG
7.7.1 Bachem Holding AG Details
7.7.2 Bachem Holding AG Major Business
7.7.3 Bachem Holding AG Peptide and Oligonucleotide CDMO Product and Services
7.7.4 Bachem Holding AG Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Bachem Holding AG Recent Developments/Updates
7.7.6 Bachem Holding AG Competitive Strengths & Weaknesses
7.8 Wuxi Apptec Co., Ltd.
7.8.1 Wuxi Apptec Co., Ltd. Details
7.8.2 Wuxi Apptec Co., Ltd. Major Business
7.8.3 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Product and Services
7.8.4 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Wuxi Apptec Co., Ltd. Recent Developments/Updates
7.8.6 Wuxi Apptec Co., Ltd. Competitive Strengths & Weaknesses
7.9 Ajinomoto Co., Inc.
7.9.1 Ajinomoto Co., Inc. Details
7.9.2 Ajinomoto Co., Inc. Major Business
7.9.3 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Product and Services
7.9.4 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Ajinomoto Co., Inc. Recent Developments/Updates
7.9.6 Ajinomoto Co., Inc. Competitive Strengths & Weaknesses
7.10 Rentschler Biopharma SE
7.10.1 Rentschler Biopharma SE Details
7.10.2 Rentschler Biopharma SE Major Business
7.10.3 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Product and Services
7.10.4 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Rentschler Biopharma SE Recent Developments/Updates
7.10.6 Rentschler Biopharma SE Competitive Strengths & Weaknesses
7.11 Corden Pharma GmbH
7.11.1 Corden Pharma GmbH Details
7.11.2 Corden Pharma GmbH Major Business
7.11.3 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Product and Services
7.11.4 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Corden Pharma GmbH Recent Developments/Updates
7.11.6 Corden Pharma GmbH Competitive Strengths & Weaknesses
7.12 Senn Chemicals AG
7.12.1 Senn Chemicals AG Details
7.12.2 Senn Chemicals AG Major Business
7.12.3 Senn Chemicals AG Peptide and Oligonucleotide CDMO Product and Services
7.12.4 Senn Chemicals AG Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Senn Chemicals AG Recent Developments/Updates
7.12.6 Senn Chemicals AG Competitive Strengths & Weaknesses
7.13 Almac Group
7.13.1 Almac Group Details
7.13.2 Almac Group Major Business
7.13.3 Almac Group Peptide and Oligonucleotide CDMO Product and Services
7.13.4 Almac Group Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 Almac Group Recent Developments/Updates
7.13.6 Almac Group Competitive Strengths & Weaknesses
7.14 Lonza Custom Manufacturing
7.14.1 Lonza Custom Manufacturing Details
7.14.2 Lonza Custom Manufacturing Major Business
7.14.3 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Product and Services
7.14.4 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 Lonza Custom Manufacturing Recent Developments/Updates
7.14.6 Lonza Custom Manufacturing Competitive Strengths & Weaknesses
7.15 Creative Peptides
7.15.1 Creative Peptides Details
7.15.2 Creative Peptides Major Business
7.15.3 Creative Peptides Peptide and Oligonucleotide CDMO Product and Services
7.15.4 Creative Peptides Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Creative Peptides Recent Developments/Updates
7.15.6 Creative Peptides Competitive Strengths & Weaknesses
7.16 Swiss Customized Synthesis
7.16.1 Swiss Customized Synthesis Details
7.16.2 Swiss Customized Synthesis Major Business
7.16.3 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Product and Services
7.16.4 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.16.5 Swiss Customized Synthesis Recent Developments/Updates
7.16.6 Swiss Customized Synthesis Competitive Strengths & Weaknesses
7.17 Syngene
7.17.1 Syngene Details
7.17.2 Syngene Major Business
7.17.3 Syngene Peptide and Oligonucleotide CDMO Product and Services
7.17.4 Syngene Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.17.5 Syngene Recent Developments/Updates
7.17.6 Syngene Competitive Strengths & Weaknesses
7.18 Eurogentec
7.18.1 Eurogentec Details
7.18.2 Eurogentec Major Business
7.18.3 Eurogentec Peptide and Oligonucleotide CDMO Product and Services
7.18.4 Eurogentec Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.18.5 Eurogentec Recent Developments/Updates
7.18.6 Eurogentec Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Peptide and Oligonucleotide CDMO Industry Chain
8.2 Peptide and Oligonucleotide CDMO Upstream Analysis
8.3 Peptide and Oligonucleotide CDMO Midstream Analysis
8.4 Peptide and Oligonucleotide CDMO Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Peptide and Oligonucleotide CDMO Introduction
1.2 World Peptide and Oligonucleotide CDMO Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Peptide and Oligonucleotide CDMO Total Market by Region (by Headquarter Location)
1.3.1 World Peptide and Oligonucleotide CDMO Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Peptide and Oligonucleotide CDMO Market Size (2018-2029)
1.3.3 China Peptide and Oligonucleotide CDMO Market Size (2018-2029)
1.3.4 Europe Peptide and Oligonucleotide CDMO Market Size (2018-2029)
1.3.5 Japan Peptide and Oligonucleotide CDMO Market Size (2018-2029)
1.3.6 South Korea Peptide and Oligonucleotide CDMO Market Size (2018-2029)
1.3.7 ASEAN Peptide and Oligonucleotide CDMO Market Size (2018-2029)
1.3.8 India Peptide and Oligonucleotide CDMO Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Peptide and Oligonucleotide CDMO Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Peptide and Oligonucleotide CDMO Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Peptide and Oligonucleotide CDMO Consumption Value (2018-2029)
2.2 World Peptide and Oligonucleotide CDMO Consumption Value by Region
2.2.1 World Peptide and Oligonucleotide CDMO Consumption Value by Region (2018-2023)
2.2.2 World Peptide and Oligonucleotide CDMO Consumption Value Forecast by Region (2024-2029)
2.3 United States Peptide and Oligonucleotide CDMO Consumption Value (2018-2029)
2.4 China Peptide and Oligonucleotide CDMO Consumption Value (2018-2029)
2.5 Europe Peptide and Oligonucleotide CDMO Consumption Value (2018-2029)
2.6 Japan Peptide and Oligonucleotide CDMO Consumption Value (2018-2029)
2.7 South Korea Peptide and Oligonucleotide CDMO Consumption Value (2018-2029)
2.8 ASEAN Peptide and Oligonucleotide CDMO Consumption Value (2018-2029)
2.9 India Peptide and Oligonucleotide CDMO Consumption Value (2018-2029)
3 WORLD PEPTIDE AND OLIGONUCLEOTIDE CDMO COMPANIES COMPETITIVE ANALYSIS
3.1 World Peptide and Oligonucleotide CDMO Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Peptide and Oligonucleotide CDMO Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Peptide and Oligonucleotide CDMO in 2022
3.2.3 Global Concentration Ratios (CR8) for Peptide and Oligonucleotide CDMO in 2022
3.3 Peptide and Oligonucleotide CDMO Company Evaluation Quadrant
3.4 Peptide and Oligonucleotide CDMO Market: Overall Company Footprint Analysis
3.4.1 Peptide and Oligonucleotide CDMO Market: Region Footprint
3.4.2 Peptide and Oligonucleotide CDMO Market: Company Product Type Footprint
3.4.3 Peptide and Oligonucleotide CDMO Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Peptide and Oligonucleotide CDMO Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Peptide and Oligonucleotide CDMO Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Peptide and Oligonucleotide CDMO Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Peptide and Oligonucleotide CDMO Consumption Value Comparison
4.2.1 United States VS China: Peptide and Oligonucleotide CDMO Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Peptide and Oligonucleotide CDMO Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Peptide and Oligonucleotide CDMO Companies and Market Share, 2018-2023
4.3.1 United States Based Peptide and Oligonucleotide CDMO Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Peptide and Oligonucleotide CDMO Revenue, (2018-2023)
4.4 China Based Companies Peptide and Oligonucleotide CDMO Revenue and Market Share, 2018-2023
4.4.1 China Based Peptide and Oligonucleotide CDMO Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Peptide and Oligonucleotide CDMO Revenue, (2018-2023)
4.5 Rest of World Based Peptide and Oligonucleotide CDMO Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Peptide and Oligonucleotide CDMO Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Peptide and Oligonucleotide CDMO Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Peptide and Oligonucleotide CDMO Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Peptide CDMO
5.2.2 Oligonucleotide CDMO
5.3 Market Segment by Type
5.3.1 World Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
5.3.2 World Peptide and Oligonucleotide CDMO Market Size by Type (2024-2029)
5.3.3 World Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Peptide and Oligonucleotide CDMO Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Pharmaceutical and Biotechnology Companies
6.2.2 Research Institutes
6.2.3 Others
6.3 Market Segment by Application
6.3.1 World Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
6.3.2 World Peptide and Oligonucleotide CDMO Market Size by Application (2024-2029)
6.3.3 World Peptide and Oligonucleotide CDMO Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Lonza Group Ltd.
7.1.1 Lonza Group Ltd. Details
7.1.2 Lonza Group Ltd. Major Business
7.1.3 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Product and Services
7.1.4 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Lonza Group Ltd. Recent Developments/Updates
7.1.6 Lonza Group Ltd. Competitive Strengths & Weaknesses
7.2 Thermo Fisher Scientific Inc.
7.2.1 Thermo Fisher Scientific Inc. Details
7.2.2 Thermo Fisher Scientific Inc. Major Business
7.2.3 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Product and Services
7.2.4 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Thermo Fisher Scientific Inc. Recent Developments/Updates
7.2.6 Thermo Fisher Scientific Inc. Competitive Strengths & Weaknesses
7.3 Merck KGaA
7.3.1 Merck KGaA Details
7.3.2 Merck KGaA Major Business
7.3.3 Merck KGaA Peptide and Oligonucleotide CDMO Product and Services
7.3.4 Merck KGaA Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Merck KGaA Recent Developments/Updates
7.3.6 Merck KGaA Competitive Strengths & Weaknesses
7.4 Catalent, Inc.
7.4.1 Catalent, Inc. Details
7.4.2 Catalent, Inc. Major Business
7.4.3 Catalent, Inc. Peptide and Oligonucleotide CDMO Product and Services
7.4.4 Catalent, Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Catalent, Inc. Recent Developments/Updates
7.4.6 Catalent, Inc. Competitive Strengths & Weaknesses
7.5 Genscript Biotech Corporation
7.5.1 Genscript Biotech Corporation Details
7.5.2 Genscript Biotech Corporation Major Business
7.5.3 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Product and Services
7.5.4 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Genscript Biotech Corporation Recent Developments/Updates
7.5.6 Genscript Biotech Corporation Competitive Strengths & Weaknesses
7.6 Polypeptide Group
7.6.1 Polypeptide Group Details
7.6.2 Polypeptide Group Major Business
7.6.3 Polypeptide Group Peptide and Oligonucleotide CDMO Product and Services
7.6.4 Polypeptide Group Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Polypeptide Group Recent Developments/Updates
7.6.6 Polypeptide Group Competitive Strengths & Weaknesses
7.7 Bachem Holding AG
7.7.1 Bachem Holding AG Details
7.7.2 Bachem Holding AG Major Business
7.7.3 Bachem Holding AG Peptide and Oligonucleotide CDMO Product and Services
7.7.4 Bachem Holding AG Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Bachem Holding AG Recent Developments/Updates
7.7.6 Bachem Holding AG Competitive Strengths & Weaknesses
7.8 Wuxi Apptec Co., Ltd.
7.8.1 Wuxi Apptec Co., Ltd. Details
7.8.2 Wuxi Apptec Co., Ltd. Major Business
7.8.3 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Product and Services
7.8.4 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Wuxi Apptec Co., Ltd. Recent Developments/Updates
7.8.6 Wuxi Apptec Co., Ltd. Competitive Strengths & Weaknesses
7.9 Ajinomoto Co., Inc.
7.9.1 Ajinomoto Co., Inc. Details
7.9.2 Ajinomoto Co., Inc. Major Business
7.9.3 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Product and Services
7.9.4 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Ajinomoto Co., Inc. Recent Developments/Updates
7.9.6 Ajinomoto Co., Inc. Competitive Strengths & Weaknesses
7.10 Rentschler Biopharma SE
7.10.1 Rentschler Biopharma SE Details
7.10.2 Rentschler Biopharma SE Major Business
7.10.3 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Product and Services
7.10.4 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Rentschler Biopharma SE Recent Developments/Updates
7.10.6 Rentschler Biopharma SE Competitive Strengths & Weaknesses
7.11 Corden Pharma GmbH
7.11.1 Corden Pharma GmbH Details
7.11.2 Corden Pharma GmbH Major Business
7.11.3 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Product and Services
7.11.4 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Corden Pharma GmbH Recent Developments/Updates
7.11.6 Corden Pharma GmbH Competitive Strengths & Weaknesses
7.12 Senn Chemicals AG
7.12.1 Senn Chemicals AG Details
7.12.2 Senn Chemicals AG Major Business
7.12.3 Senn Chemicals AG Peptide and Oligonucleotide CDMO Product and Services
7.12.4 Senn Chemicals AG Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Senn Chemicals AG Recent Developments/Updates
7.12.6 Senn Chemicals AG Competitive Strengths & Weaknesses
7.13 Almac Group
7.13.1 Almac Group Details
7.13.2 Almac Group Major Business
7.13.3 Almac Group Peptide and Oligonucleotide CDMO Product and Services
7.13.4 Almac Group Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 Almac Group Recent Developments/Updates
7.13.6 Almac Group Competitive Strengths & Weaknesses
7.14 Lonza Custom Manufacturing
7.14.1 Lonza Custom Manufacturing Details
7.14.2 Lonza Custom Manufacturing Major Business
7.14.3 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Product and Services
7.14.4 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 Lonza Custom Manufacturing Recent Developments/Updates
7.14.6 Lonza Custom Manufacturing Competitive Strengths & Weaknesses
7.15 Creative Peptides
7.15.1 Creative Peptides Details
7.15.2 Creative Peptides Major Business
7.15.3 Creative Peptides Peptide and Oligonucleotide CDMO Product and Services
7.15.4 Creative Peptides Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Creative Peptides Recent Developments/Updates
7.15.6 Creative Peptides Competitive Strengths & Weaknesses
7.16 Swiss Customized Synthesis
7.16.1 Swiss Customized Synthesis Details
7.16.2 Swiss Customized Synthesis Major Business
7.16.3 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Product and Services
7.16.4 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.16.5 Swiss Customized Synthesis Recent Developments/Updates
7.16.6 Swiss Customized Synthesis Competitive Strengths & Weaknesses
7.17 Syngene
7.17.1 Syngene Details
7.17.2 Syngene Major Business
7.17.3 Syngene Peptide and Oligonucleotide CDMO Product and Services
7.17.4 Syngene Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.17.5 Syngene Recent Developments/Updates
7.17.6 Syngene Competitive Strengths & Weaknesses
7.18 Eurogentec
7.18.1 Eurogentec Details
7.18.2 Eurogentec Major Business
7.18.3 Eurogentec Peptide and Oligonucleotide CDMO Product and Services
7.18.4 Eurogentec Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
7.18.5 Eurogentec Recent Developments/Updates
7.18.6 Eurogentec Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Peptide and Oligonucleotide CDMO Industry Chain
8.2 Peptide and Oligonucleotide CDMO Upstream Analysis
8.3 Peptide and Oligonucleotide CDMO Midstream Analysis
8.4 Peptide and Oligonucleotide CDMO Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Peptide and Oligonucleotide CDMO Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Peptide and Oligonucleotide CDMO Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Peptide and Oligonucleotide CDMO Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Peptide and Oligonucleotide CDMO Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Peptide and Oligonucleotide CDMO Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Peptide and Oligonucleotide CDMO Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Peptide and Oligonucleotide CDMO Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Peptide and Oligonucleotide CDMO Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Peptide and Oligonucleotide CDMO Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Peptide and Oligonucleotide CDMO Players in 2022
Table 12. World Peptide and Oligonucleotide CDMO Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Peptide and Oligonucleotide CDMO Company Evaluation Quadrant
Table 14. Head Office of Key Peptide and Oligonucleotide CDMO Player
Table 15. Peptide and Oligonucleotide CDMO Market: Company Product Type Footprint
Table 16. Peptide and Oligonucleotide CDMO Market: Company Product Application Footprint
Table 17. Peptide and Oligonucleotide CDMO Mergers & Acquisitions Activity
Table 18. United States VS China Peptide and Oligonucleotide CDMO Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Peptide and Oligonucleotide CDMO Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Peptide and Oligonucleotide CDMO Companies, Headquarters (States, Country)
Table 21. United States Based Companies Peptide and Oligonucleotide CDMO Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Peptide and Oligonucleotide CDMO Revenue Market Share (2018-2023)
Table 23. China Based Peptide and Oligonucleotide CDMO Companies, Headquarters (Province, Country)
Table 24. China Based Companies Peptide and Oligonucleotide CDMO Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Peptide and Oligonucleotide CDMO Revenue Market Share (2018-2023)
Table 26. Rest of World Based Peptide and Oligonucleotide CDMO Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Peptide and Oligonucleotide CDMO Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Peptide and Oligonucleotide CDMO Revenue Market Share (2018-2023)
Table 29. World Peptide and Oligonucleotide CDMO Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) & (USD Million)
Table 31. World Peptide and Oligonucleotide CDMO Market Size by Type (2024-2029) & (USD Million)
Table 32. World Peptide and Oligonucleotide CDMO Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) & (USD Million)
Table 34. World Peptide and Oligonucleotide CDMO Market Size by Application (2024-2029) & (USD Million)
Table 35. Lonza Group Ltd. Basic Information, Area Served and Competitors
Table 36. Lonza Group Ltd. Major Business
Table 37. Lonza Group Ltd. Peptide and Oligonucleotide CDMO Product and Services
Table 38. Lonza Group Ltd. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Lonza Group Ltd. Recent Developments/Updates
Table 40. Lonza Group Ltd. Competitive Strengths & Weaknesses
Table 41. Thermo Fisher Scientific Inc. Basic Information, Area Served and Competitors
Table 42. Thermo Fisher Scientific Inc. Major Business
Table 43. Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Product and Services
Table 44. Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Thermo Fisher Scientific Inc. Recent Developments/Updates
Table 46. Thermo Fisher Scientific Inc. Competitive Strengths & Weaknesses
Table 47. Merck KGaA Basic Information, Area Served and Competitors
Table 48. Merck KGaA Major Business
Table 49. Merck KGaA Peptide and Oligonucleotide CDMO Product and Services
Table 50. Merck KGaA Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Merck KGaA Recent Developments/Updates
Table 52. Merck KGaA Competitive Strengths & Weaknesses
Table 53. Catalent, Inc. Basic Information, Area Served and Competitors
Table 54. Catalent, Inc. Major Business
Table 55. Catalent, Inc. Peptide and Oligonucleotide CDMO Product and Services
Table 56. Catalent, Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Catalent, Inc. Recent Developments/Updates
Table 58. Catalent, Inc. Competitive Strengths & Weaknesses
Table 59. Genscript Biotech Corporation Basic Information, Area Served and Competitors
Table 60. Genscript Biotech Corporation Major Business
Table 61. Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Product and Services
Table 62. Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Genscript Biotech Corporation Recent Developments/Updates
Table 64. Genscript Biotech Corporation Competitive Strengths & Weaknesses
Table 65. Polypeptide Group Basic Information, Area Served and Competitors
Table 66. Polypeptide Group Major Business
Table 67. Polypeptide Group Peptide and Oligonucleotide CDMO Product and Services
Table 68. Polypeptide Group Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Polypeptide Group Recent Developments/Updates
Table 70. Polypeptide Group Competitive Strengths & Weaknesses
Table 71. Bachem Holding AG Basic Information, Area Served and Competitors
Table 72. Bachem Holding AG Major Business
Table 73. Bachem Holding AG Peptide and Oligonucleotide CDMO Product and Services
Table 74. Bachem Holding AG Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Bachem Holding AG Recent Developments/Updates
Table 76. Bachem Holding AG Competitive Strengths & Weaknesses
Table 77. Wuxi Apptec Co., Ltd. Basic Information, Area Served and Competitors
Table 78. Wuxi Apptec Co., Ltd. Major Business
Table 79. Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Product and Services
Table 80. Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Wuxi Apptec Co., Ltd. Recent Developments/Updates
Table 82. Wuxi Apptec Co., Ltd. Competitive Strengths & Weaknesses
Table 83. Ajinomoto Co., Inc. Basic Information, Area Served and Competitors
Table 84. Ajinomoto Co., Inc. Major Business
Table 85. Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Product and Services
Table 86. Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Ajinomoto Co., Inc. Recent Developments/Updates
Table 88. Ajinomoto Co., Inc. Competitive Strengths & Weaknesses
Table 89. Rentschler Biopharma SE Basic Information, Area Served and Competitors
Table 90. Rentschler Biopharma SE Major Business
Table 91. Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Product and Services
Table 92. Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Rentschler Biopharma SE Recent Developments/Updates
Table 94. Rentschler Biopharma SE Competitive Strengths & Weaknesses
Table 95. Corden Pharma GmbH Basic Information, Area Served and Competitors
Table 96. Corden Pharma GmbH Major Business
Table 97. Corden Pharma GmbH Peptide and Oligonucleotide CDMO Product and Services
Table 98. Corden Pharma GmbH Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Corden Pharma GmbH Recent Developments/Updates
Table 100. Corden Pharma GmbH Competitive Strengths & Weaknesses
Table 101. Senn Chemicals AG Basic Information, Area Served and Competitors
Table 102. Senn Chemicals AG Major Business
Table 103. Senn Chemicals AG Peptide and Oligonucleotide CDMO Product and Services
Table 104. Senn Chemicals AG Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Senn Chemicals AG Recent Developments/Updates
Table 106. Senn Chemicals AG Competitive Strengths & Weaknesses
Table 107. Almac Group Basic Information, Area Served and Competitors
Table 108. Almac Group Major Business
Table 109. Almac Group Peptide and Oligonucleotide CDMO Product and Services
Table 110. Almac Group Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Almac Group Recent Developments/Updates
Table 112. Almac Group Competitive Strengths & Weaknesses
Table 113. Lonza Custom Manufacturing Basic Information, Area Served and Competitors
Table 114. Lonza Custom Manufacturing Major Business
Table 115. Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Product and Services
Table 116. Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. Lonza Custom Manufacturing Recent Developments/Updates
Table 118. Lonza Custom Manufacturing Competitive Strengths & Weaknesses
Table 119. Creative Peptides Basic Information, Area Served and Competitors
Table 120. Creative Peptides Major Business
Table 121. Creative Peptides Peptide and Oligonucleotide CDMO Product and Services
Table 122. Creative Peptides Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 123. Creative Peptides Recent Developments/Updates
Table 124. Creative Peptides Competitive Strengths & Weaknesses
Table 125. Swiss Customized Synthesis Basic Information, Area Served and Competitors
Table 126. Swiss Customized Synthesis Major Business
Table 127. Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Product and Services
Table 128. Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 129. Swiss Customized Synthesis Recent Developments/Updates
Table 130. Swiss Customized Synthesis Competitive Strengths & Weaknesses
Table 131. Syngene Basic Information, Area Served and Competitors
Table 132. Syngene Major Business
Table 133. Syngene Peptide and Oligonucleotide CDMO Product and Services
Table 134. Syngene Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 135. Syngene Recent Developments/Updates
Table 136. Eurogentec Basic Information, Area Served and Competitors
Table 137. Eurogentec Major Business
Table 138. Eurogentec Peptide and Oligonucleotide CDMO Product and Services
Table 139. Eurogentec Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 140. Global Key Players of Peptide and Oligonucleotide CDMO Upstream (Raw Materials)
Table 141. Peptide and Oligonucleotide CDMO Typical Customers
Table 1. World Peptide and Oligonucleotide CDMO Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Peptide and Oligonucleotide CDMO Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Peptide and Oligonucleotide CDMO Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Peptide and Oligonucleotide CDMO Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Peptide and Oligonucleotide CDMO Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Peptide and Oligonucleotide CDMO Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Peptide and Oligonucleotide CDMO Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Peptide and Oligonucleotide CDMO Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Peptide and Oligonucleotide CDMO Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Peptide and Oligonucleotide CDMO Players in 2022
Table 12. World Peptide and Oligonucleotide CDMO Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Peptide and Oligonucleotide CDMO Company Evaluation Quadrant
Table 14. Head Office of Key Peptide and Oligonucleotide CDMO Player
Table 15. Peptide and Oligonucleotide CDMO Market: Company Product Type Footprint
Table 16. Peptide and Oligonucleotide CDMO Market: Company Product Application Footprint
Table 17. Peptide and Oligonucleotide CDMO Mergers & Acquisitions Activity
Table 18. United States VS China Peptide and Oligonucleotide CDMO Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Peptide and Oligonucleotide CDMO Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Peptide and Oligonucleotide CDMO Companies, Headquarters (States, Country)
Table 21. United States Based Companies Peptide and Oligonucleotide CDMO Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Peptide and Oligonucleotide CDMO Revenue Market Share (2018-2023)
Table 23. China Based Peptide and Oligonucleotide CDMO Companies, Headquarters (Province, Country)
Table 24. China Based Companies Peptide and Oligonucleotide CDMO Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Peptide and Oligonucleotide CDMO Revenue Market Share (2018-2023)
Table 26. Rest of World Based Peptide and Oligonucleotide CDMO Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Peptide and Oligonucleotide CDMO Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Peptide and Oligonucleotide CDMO Revenue Market Share (2018-2023)
Table 29. World Peptide and Oligonucleotide CDMO Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) & (USD Million)
Table 31. World Peptide and Oligonucleotide CDMO Market Size by Type (2024-2029) & (USD Million)
Table 32. World Peptide and Oligonucleotide CDMO Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) & (USD Million)
Table 34. World Peptide and Oligonucleotide CDMO Market Size by Application (2024-2029) & (USD Million)
Table 35. Lonza Group Ltd. Basic Information, Area Served and Competitors
Table 36. Lonza Group Ltd. Major Business
Table 37. Lonza Group Ltd. Peptide and Oligonucleotide CDMO Product and Services
Table 38. Lonza Group Ltd. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Lonza Group Ltd. Recent Developments/Updates
Table 40. Lonza Group Ltd. Competitive Strengths & Weaknesses
Table 41. Thermo Fisher Scientific Inc. Basic Information, Area Served and Competitors
Table 42. Thermo Fisher Scientific Inc. Major Business
Table 43. Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Product and Services
Table 44. Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Thermo Fisher Scientific Inc. Recent Developments/Updates
Table 46. Thermo Fisher Scientific Inc. Competitive Strengths & Weaknesses
Table 47. Merck KGaA Basic Information, Area Served and Competitors
Table 48. Merck KGaA Major Business
Table 49. Merck KGaA Peptide and Oligonucleotide CDMO Product and Services
Table 50. Merck KGaA Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Merck KGaA Recent Developments/Updates
Table 52. Merck KGaA Competitive Strengths & Weaknesses
Table 53. Catalent, Inc. Basic Information, Area Served and Competitors
Table 54. Catalent, Inc. Major Business
Table 55. Catalent, Inc. Peptide and Oligonucleotide CDMO Product and Services
Table 56. Catalent, Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Catalent, Inc. Recent Developments/Updates
Table 58. Catalent, Inc. Competitive Strengths & Weaknesses
Table 59. Genscript Biotech Corporation Basic Information, Area Served and Competitors
Table 60. Genscript Biotech Corporation Major Business
Table 61. Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Product and Services
Table 62. Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Genscript Biotech Corporation Recent Developments/Updates
Table 64. Genscript Biotech Corporation Competitive Strengths & Weaknesses
Table 65. Polypeptide Group Basic Information, Area Served and Competitors
Table 66. Polypeptide Group Major Business
Table 67. Polypeptide Group Peptide and Oligonucleotide CDMO Product and Services
Table 68. Polypeptide Group Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Polypeptide Group Recent Developments/Updates
Table 70. Polypeptide Group Competitive Strengths & Weaknesses
Table 71. Bachem Holding AG Basic Information, Area Served and Competitors
Table 72. Bachem Holding AG Major Business
Table 73. Bachem Holding AG Peptide and Oligonucleotide CDMO Product and Services
Table 74. Bachem Holding AG Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Bachem Holding AG Recent Developments/Updates
Table 76. Bachem Holding AG Competitive Strengths & Weaknesses
Table 77. Wuxi Apptec Co., Ltd. Basic Information, Area Served and Competitors
Table 78. Wuxi Apptec Co., Ltd. Major Business
Table 79. Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Product and Services
Table 80. Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Wuxi Apptec Co., Ltd. Recent Developments/Updates
Table 82. Wuxi Apptec Co., Ltd. Competitive Strengths & Weaknesses
Table 83. Ajinomoto Co., Inc. Basic Information, Area Served and Competitors
Table 84. Ajinomoto Co., Inc. Major Business
Table 85. Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Product and Services
Table 86. Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Ajinomoto Co., Inc. Recent Developments/Updates
Table 88. Ajinomoto Co., Inc. Competitive Strengths & Weaknesses
Table 89. Rentschler Biopharma SE Basic Information, Area Served and Competitors
Table 90. Rentschler Biopharma SE Major Business
Table 91. Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Product and Services
Table 92. Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Rentschler Biopharma SE Recent Developments/Updates
Table 94. Rentschler Biopharma SE Competitive Strengths & Weaknesses
Table 95. Corden Pharma GmbH Basic Information, Area Served and Competitors
Table 96. Corden Pharma GmbH Major Business
Table 97. Corden Pharma GmbH Peptide and Oligonucleotide CDMO Product and Services
Table 98. Corden Pharma GmbH Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Corden Pharma GmbH Recent Developments/Updates
Table 100. Corden Pharma GmbH Competitive Strengths & Weaknesses
Table 101. Senn Chemicals AG Basic Information, Area Served and Competitors
Table 102. Senn Chemicals AG Major Business
Table 103. Senn Chemicals AG Peptide and Oligonucleotide CDMO Product and Services
Table 104. Senn Chemicals AG Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Senn Chemicals AG Recent Developments/Updates
Table 106. Senn Chemicals AG Competitive Strengths & Weaknesses
Table 107. Almac Group Basic Information, Area Served and Competitors
Table 108. Almac Group Major Business
Table 109. Almac Group Peptide and Oligonucleotide CDMO Product and Services
Table 110. Almac Group Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Almac Group Recent Developments/Updates
Table 112. Almac Group Competitive Strengths & Weaknesses
Table 113. Lonza Custom Manufacturing Basic Information, Area Served and Competitors
Table 114. Lonza Custom Manufacturing Major Business
Table 115. Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Product and Services
Table 116. Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. Lonza Custom Manufacturing Recent Developments/Updates
Table 118. Lonza Custom Manufacturing Competitive Strengths & Weaknesses
Table 119. Creative Peptides Basic Information, Area Served and Competitors
Table 120. Creative Peptides Major Business
Table 121. Creative Peptides Peptide and Oligonucleotide CDMO Product and Services
Table 122. Creative Peptides Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 123. Creative Peptides Recent Developments/Updates
Table 124. Creative Peptides Competitive Strengths & Weaknesses
Table 125. Swiss Customized Synthesis Basic Information, Area Served and Competitors
Table 126. Swiss Customized Synthesis Major Business
Table 127. Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Product and Services
Table 128. Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 129. Swiss Customized Synthesis Recent Developments/Updates
Table 130. Swiss Customized Synthesis Competitive Strengths & Weaknesses
Table 131. Syngene Basic Information, Area Served and Competitors
Table 132. Syngene Major Business
Table 133. Syngene Peptide and Oligonucleotide CDMO Product and Services
Table 134. Syngene Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 135. Syngene Recent Developments/Updates
Table 136. Eurogentec Basic Information, Area Served and Competitors
Table 137. Eurogentec Major Business
Table 138. Eurogentec Peptide and Oligonucleotide CDMO Product and Services
Table 139. Eurogentec Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 140. Global Key Players of Peptide and Oligonucleotide CDMO Upstream (Raw Materials)
Table 141. Peptide and Oligonucleotide CDMO Typical Customers
LIST OF FIGURES
Figure 1. Peptide and Oligonucleotide CDMO Picture
Figure 2. World Peptide and Oligonucleotide CDMO Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Peptide and Oligonucleotide CDMO Total Market Size (2018-2029) & (USD Million)
Figure 4. World Peptide and Oligonucleotide CDMO Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Peptide and Oligonucleotide CDMO Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Peptide and Oligonucleotide CDMO Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Peptide and Oligonucleotide CDMO Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Peptide and Oligonucleotide CDMO Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Peptide and Oligonucleotide CDMO Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Peptide and Oligonucleotide CDMO Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Peptide and Oligonucleotide CDMO Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Peptide and Oligonucleotide CDMO Revenue (2018-2029) & (USD Million)
Figure 13. Peptide and Oligonucleotide CDMO Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Peptide and Oligonucleotide CDMO Consumption Value (2018-2029) & (USD Million)
Figure 16. World Peptide and Oligonucleotide CDMO Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Peptide and Oligonucleotide CDMO Consumption Value (2018-2029) & (USD Million)
Figure 18. China Peptide and Oligonucleotide CDMO Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Peptide and Oligonucleotide CDMO Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Peptide and Oligonucleotide CDMO Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Peptide and Oligonucleotide CDMO Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Peptide and Oligonucleotide CDMO Consumption Value (2018-2029) & (USD Million)
Figure 23. India Peptide and Oligonucleotide CDMO Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Peptide and Oligonucleotide CDMO by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Peptide and Oligonucleotide CDMO Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Peptide and Oligonucleotide CDMO Markets in 2022
Figure 27. United States VS China: Peptide and Oligonucleotide CDMO Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Peptide and Oligonucleotide CDMO Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Peptide and Oligonucleotide CDMO Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Peptide and Oligonucleotide CDMO Market Size Market Share by Type in 2022
Figure 31. Peptide CDMO
Figure 32. Oligonucleotide CDMO
Figure 33. World Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2018-2029)
Figure 34. World Peptide and Oligonucleotide CDMO Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 35. World Peptide and Oligonucleotide CDMO Market Size Market Share by Application in 2022
Figure 36. Pharmaceutical and Biotechnology Companies
Figure 37. Research Institutes
Figure 38. Others
Figure 39. Peptide and Oligonucleotide CDMO Industrial Chain
Figure 40. Methodology
Figure 41. Research Process and Data Source
Figure 1. Peptide and Oligonucleotide CDMO Picture
Figure 2. World Peptide and Oligonucleotide CDMO Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Peptide and Oligonucleotide CDMO Total Market Size (2018-2029) & (USD Million)
Figure 4. World Peptide and Oligonucleotide CDMO Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Peptide and Oligonucleotide CDMO Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Peptide and Oligonucleotide CDMO Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Peptide and Oligonucleotide CDMO Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Peptide and Oligonucleotide CDMO Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Peptide and Oligonucleotide CDMO Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Peptide and Oligonucleotide CDMO Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Peptide and Oligonucleotide CDMO Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Peptide and Oligonucleotide CDMO Revenue (2018-2029) & (USD Million)
Figure 13. Peptide and Oligonucleotide CDMO Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Peptide and Oligonucleotide CDMO Consumption Value (2018-2029) & (USD Million)
Figure 16. World Peptide and Oligonucleotide CDMO Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Peptide and Oligonucleotide CDMO Consumption Value (2018-2029) & (USD Million)
Figure 18. China Peptide and Oligonucleotide CDMO Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Peptide and Oligonucleotide CDMO Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Peptide and Oligonucleotide CDMO Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Peptide and Oligonucleotide CDMO Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Peptide and Oligonucleotide CDMO Consumption Value (2018-2029) & (USD Million)
Figure 23. India Peptide and Oligonucleotide CDMO Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Peptide and Oligonucleotide CDMO by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Peptide and Oligonucleotide CDMO Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Peptide and Oligonucleotide CDMO Markets in 2022
Figure 27. United States VS China: Peptide and Oligonucleotide CDMO Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Peptide and Oligonucleotide CDMO Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Peptide and Oligonucleotide CDMO Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Peptide and Oligonucleotide CDMO Market Size Market Share by Type in 2022
Figure 31. Peptide CDMO
Figure 32. Oligonucleotide CDMO
Figure 33. World Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2018-2029)
Figure 34. World Peptide and Oligonucleotide CDMO Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 35. World Peptide and Oligonucleotide CDMO Market Size Market Share by Application in 2022
Figure 36. Pharmaceutical and Biotechnology Companies
Figure 37. Research Institutes
Figure 38. Others
Figure 39. Peptide and Oligonucleotide CDMO Industrial Chain
Figure 40. Methodology
Figure 41. Research Process and Data Source
